Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized open-label study of flonoltinib maleate in hydroxyurea- or interferon-resistant/intolerant polycythemia vera
CTR20253643Phase 2Active
- Sponsor
- Zeling Biopharma
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of flonoltinib in polycythemia vera (PV), sponsored by Zeling Biopharma. Started Nov 2025; status: active.
02
Drugs
flonoltinib
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on CTR20253643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253643.